- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT02139930
Project 2: Strategies for Reducing Nicotine Content in Cigarettes
Studieöversikt
Status
Betingelser
Detaljerad beskrivning
Studietyp
Inskrivning (Förväntat)
Fas
- Inte tillämpbar
Kontakter och platser
Studieorter
-
-
Arizona
-
Phoenix, Arizona, Förenta staterna, 85054
- Mayo Clinic
-
-
California
-
San Francisco, California, Förenta staterna, 94143
- University of California San Francisco
-
-
Florida
-
Tampa, Florida, Förenta staterna, 33617
- Moffitt Cancer Center
-
-
Maryland
-
Baltimore, Maryland, Förenta staterna, 21224
- Johns Hopkins University
-
-
Minnesota
-
Duluth, Minnesota, Förenta staterna, 55812
- University of Minnesota Medical School Duluth
-
Minneapolis, Minnesota, Förenta staterna, 55455
- University of Minnesota
-
-
North Carolina
-
Durham, North Carolina, Förenta staterna, 27705
- Duke University
-
-
Oregon
-
Eugene, Oregon, Förenta staterna, 97403
- Oregon Research Institute
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Förenta staterna, 19104
- University of Pennsylvania
-
-
Texas
-
Houston, Texas, Förenta staterna, 77030
- MDAnderson Cancer Center
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Inclusion Criteria:
- Age 18+
- Daily smokers who smoke an average of at least five cigarettes per day for at least 1 year
- Breath CO levels > 8 ppm (if ≤ 8 ppm, then NicAlert Strip level must indicate regular smoking)
Exclusion Criteria:
- Planned quit date in the next 30 days
- Currently seeking treatment for smoking cessation
- Currently using nicotine replacement therapies or other pharmacotherapies as cessation aid (non-cessation intermittent use acceptable)
- A quit attempt in the past 30 days resulting in greater than 3 days of abstinence
- Using other tobacco products or e-cigarettes more than 9 days in the past 30 days
- Significant unstable medical conditions (Any significant change in a serious medical condition occurring during the past 3 months including, cardiovascular disease, COPD, and cancer, as determined by the licensed medical professional at each site)
- Unstable psychiatric conditions (Any significant change in psychiatric symptoms during the past 3 months as determined by the licensed medical professional at each site)
- Schizophrenia and schizoaffective disorder
- Psychiatric medication changes (e.g., new prescriptions, changes in dosages, or discontinuation of medications) in the past 3 months that was a result of negative changes in symptoms.
Positive toxicology screen for any of the following drugs: cocaine, opiates, methadone, benzodiazepines, barbiturates, amphetamines, methamphetamines, and PCP
- Marijuana will be tested for but will not be an exclusionary criterion.
- Participants with valid prescriptions for opiates, benzodiazepines, barbiturates, amphetamines or methadone will not be excluded.
- Participants failing the toxicology screen will be allowed to re-screen once.
Blood alcohol level > 0.01
a. Participants failing the blood alcohol screen will be allowed to re-screen once.
- Binge drinking alcohol (more than 9 days in the past 30 days, 4/5 drinks per day (female/male))
- Pregnant, trying to become pregnant or breastfeeding
- Predominant use of 'roll your own cigarettes'
- CO reading >80 ppm
Systolic BP greater than or equal to 160
a. Participants failing for blood pressure will be allowed to re-screen once.
Diastolic BP greater than or equal to 100
a. Participants failing for blood pressure will be allowed to re-screen once.
Systolic BP below 90 and symptomatic (dizziness, extreme fatigue, difficulty thinking, inability to stand or walk, feeling faint)
a. Participants failing for blood pressure will be allowed to re-screen once.
Diastolic BP below 50 and symptomatic (dizziness, extreme fatigue, difficulty thinking, inability to stand or walk, feeling faint)
a. Participants failing for blood pressure will be allowed to re-screen once.
Heart rate greater than or equal to 105 bpm
a. Participants failing for heart rate will be allowed to re-screen once.
Heart rate lower than 45 bpm and symptomatic (dizziness, extreme fatigue, difficulty thinking, inability to stand or walk, feeling faint)
a. Participants failing for heart rate will be allowed to re-screen once.
- Indicating any suicidal ideation in the past month, suicide attempts in the past 5 years (if within past 5 to 10 years, requires physician approval), or score of >4 on the MINI suicide subscale
- Household member enrolled in the study concurrently.
- Inability to independently read and comprehend the consent form and other written study materials and measures because participants are required to complete parts of the protocol at home independently.
- Participated in prior study that involved reduced nicotine content cigarettes.
- Having participated in a research study during the past three months in a study that would impact baseline smoking or response to study products.
Currently taking the following anticonvulsant medications:
- Phenytoin [Brand Name: Dilantin]
- Carbamazepine [Brand Name: Tegretol, Carbatrol, Equetro, Epitol]
- Oxcarbazepine [Brand Name: Trileptal]
- Primidone [Brand Name: Mysoline]
- Phenobarbital
Currently taking the following medication:
- Bendamustine (Treanda)
- Clopidogrel (Plavix)
- Clozapine (Clozaril, FazaClo)
- Erlotinib (Tarceva)
- Flecainide (Tambocor)
- Fluvoxamine (Luvox)
- Irinotecan (Camptosar)
- Olanzapine (Zyprexa)
- Ropinirole (Requip)
- Tacrine (Cognex)
- Theophylline (Theo Dur, etc.)
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Grundläggande vetenskap
- Tilldelning: Randomiserad
- Interventionsmodell: Parallellt uppdrag
- Maskning: Dubbel
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
---|---|
Aktiv komparator: Normal Nicotine Control Group
These subjects will smoke normal nicotine content Spectrum brand cigarettes for 20 weeks.
|
Participants will smoke experimental cigarettes for a period of 20-weeks.
|
Experimentell: Immediate Nicotine Reduction Group
This group will immediately be switched to smoking very low nicotine content (VLNC) Spectrum brand cigarettes.
They will smoke these cigarettes for 20 weeks.
|
Participants will smoke experimental cigarettes for a period of 20-weeks.
|
Experimentell: Gradual Nicotine Reduction Group
This group will smoke progressively lower nicotine content Spectrum brand cigarettes for a period of one month each until they end up smoking the same VLNC cigarettes as the immediate reduction group.
|
Participants will smoke experimental cigarettes for a period of 20-weeks.
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
---|---|---|
Toxicant exposure pattern: Expired air carbon monoxide
Tidsram: 20-week treatment period
|
Between group comparison of expired air carbon monoxide (CO) values at week 20 using baseline CO values as a covariate.
|
20-week treatment period
|
Toxicant exposure pattern: Urinary phenanthrene tetroal (Phe)
Tidsram: 20-week treatment period
|
Between group comparison of urinary phenanthrene tetroal values at week 20 using baseline values as a covariate.
|
20-week treatment period
|
Toxicant exposure pattern: Urinary mercapturic acids of acrolein
Tidsram: 20-week treatment period
|
Between group comparison of urinary mercapturic acid level at week 20 using baseline values as a covariate.
|
20-week treatment period
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
---|---|---|
Nicotine exposure: Total nicotine equivalents (TNE)
Tidsram: End of treatment (Week 20)
|
Between group comparison of urinary total nicotine equivalents at week 20 using baseline values as a covariate.
|
End of treatment (Week 20)
|
Other toxicant exposure: Tobacco specific nitrosamines-Total NNAL and NNN
Tidsram: End of treatment (Week 20)
|
Between group comparison of urinary total NNAL and NNN levels at week 20 using baseline values as a covariate.
|
End of treatment (Week 20)
|
Effect biomarker: C-Reactive protein-high sensitivity as an inflammation biomarker
Tidsram: End of treatment (Week 20)
|
Between group comparison of C-Reactive protein levels in serum at week 20 using baseline values as a covariate.
|
End of treatment (Week 20)
|
Measure of acceptability: Retention in study
Tidsram: End of treatment (Week 20)
|
Between group comparison of early termination from the study.
|
End of treatment (Week 20)
|
Measure of acceptability: Non-compliance
Tidsram: End of treatment (Week 20)
|
Between group comparison of use of non-study tobacco products.
|
End of treatment (Week 20)
|
Effect biomarker: 8-epi-PGF2α as a biomarker for oxidative stress
Tidsram: End of treatment (Week 20)
|
Between group comparison of 8-epi-PGF2α at week 20 using baseline values as a covariate.
|
End of treatment (Week 20)
|
Effect biomarker: White blood cells count as inflammation biomarker
Tidsram: End of treatment (Week 20)
|
Between group comparison of white blood cell count at week 20 using baseline values as a covariate.
|
End of treatment (Week 20)
|
Nicotine exposure: Urinary cotinine
Tidsram: End of treatment (Week 20)
|
Between group comparison of urinary total nicotine equivalents at week 20 using baseline values as a covariate.
|
End of treatment (Week 20)
|
Samarbetspartners och utredare
Samarbetspartners
Utredare
- Huvudutredare: Eric Donny, PhD, University of Pittsburgh
Publikationer och användbara länkar
Studieavstämningsdatum
Studera stora datum
Studiestart
Primärt slutförande (Faktisk)
Avslutad studie (Faktisk)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Uppskatta)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Nyckelord
Ytterligare relevanta MeSH-villkor
- Mentala störningar
- Kemiskt inducerade störningar
- Substansrelaterade störningar
- Störning av tobaksbruk
- Läkemedels fysiologiska effekter
- Neurotransmittormedel
- Molekylära mekanismer för farmakologisk verkan
- Autonoma agenter
- Agenter från det perifera nervsystemet
- Kolinerga medel
- Ganglionstimulerande medel
- Nikotinagonister
- Kolinerga agonister
- Nikotin
Andra studie-ID-nummer
- U54 DA031659-P2
- U54DA031659 (U.S.S. NIH-anslag/kontrakt)
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .
Kliniska prövningar på Tobaksrökning
-
Eunice Kennedy Shriver National Institute of Child...AvslutadEnvironmental Tobacco Smoke (ETS)Förenta staterna
Kliniska prövningar på Normal Nicotine Control Group
-
Freie Universität BerlinAvslutadDiabetes mellitus, typ 2Tyskland
-
Duke UniversityNational Institute of Nursing Research (NINR); National Institutes of Health...Aktiv, inte rekryterandeKroniska njursjukdomar | Diabetes mellitus, typ 1 | Systemisk lupus erythematosus | Inflammatoriska tarmsjukdomar | Cystisk fibros | Sicklecellanemi | Stamcellstransplantation | Barncancer | OrgantransplantationFörenta staterna
-
University of California, San FranciscoMount Zion Health Fund; Pritzker Family Foundation; Mental Insight FoundationAvslutadDepression, unipolärFörenta staterna
-
Bright Cloud International CorpNational Cancer Institute (NCI); Rutgers, The State University of New JerseyRekryteringTelerehabilitering Kognitiv funktionsnedsättning efter genomförbarhetsstudie för kemoterapi (TCIFCF)Kognitiv funktionsnedsättning, lättFörenta staterna
-
VA Pittsburgh Healthcare SystemUniversity of PittsburghAvslutad
-
Rush University Medical CenterRekryteringSubstansanvändning | Våld i tonåren | Undvikande av sjukvårdFörenta staterna
-
The University of Texas Health Science Center,...RekryteringLäpp- och gomspaltFörenta staterna
-
Federico II UniversityAvslutadFriska | Övervikt och fetmaItalien
-
University of Illinois at ChicagoNational Institute of Nursing Research (NINR); National Institutes of Health...AvslutadRörlighetsbegränsningFörenta staterna
-
National Institute of Diabetes and Digestive and...Detroit Department of HealthAvslutad